These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
112 related articles for article (PubMed ID: 21296193)
1. Does polymorphysm of genes coding for pro-inflammatory mediators predict the clinical response to tnf alpha blocking agents? A review analysis of the literature. Ingegnoli F; Favalli EG; Meroni PL Autoimmun Rev; 2011 Jun; 10(8):460-3. PubMed ID: 21296193 [TBL] [Abstract][Full Text] [Related]
2. An update on pharmacogenomics in rheumatoid arthritis with a focus on TNF-blocking agents. Ranganathan P Curr Opin Mol Ther; 2008 Dec; 10(6):562-7. PubMed ID: 19051134 [TBL] [Abstract][Full Text] [Related]
3. Predictors of response to anti-TNF-alpha therapy among patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register. Hyrich KL; Watson KD; Silman AJ; Symmons DP; Rheumatology (Oxford); 2006 Dec; 45(12):1558-65. PubMed ID: 16705046 [TBL] [Abstract][Full Text] [Related]
4. Genetic and genomic predictors of anti-TNF response. Prajapati R; Plant D; Barton A Pharmacogenomics; 2011 Nov; 12(11):1571-85. PubMed ID: 22044414 [TBL] [Abstract][Full Text] [Related]
5. Clinical trial outcome of anti-tumour necrosis factor alpha therapy in rheumatic arthritis. Choy E Cytokine; 2004 Nov 21-Dec 7; 28(4-5):158-61. PubMed ID: 15588689 [TBL] [Abstract][Full Text] [Related]
6. [Current aspects of cost effectiveness of TNF-alpha blocking agents in patients with rheumatoid arthritis]. Merkesdal S; Ruof J Z Rheumatol; 2002; 61 Suppl 2():II/29-32. PubMed ID: 12491120 [TBL] [Abstract][Full Text] [Related]
7. Pharmacogenomics of tumor necrosis factor antagonists in rheumatoid arthritis. Ranganathan P Pharmacogenomics; 2005 Jul; 6(5):481-90. PubMed ID: 16013998 [TBL] [Abstract][Full Text] [Related]
8. Genetic variants that predict response to anti-tumor necrosis factor therapy in rheumatoid arthritis: current challenges and future directions. Plenge RM; Criswell LA Curr Opin Rheumatol; 2008 Mar; 20(2):145-52. PubMed ID: 18349743 [TBL] [Abstract][Full Text] [Related]
9. Potential novel biomarkers of disease activity in rheumatoid arthritis patients: CXCL13, CCL23, transforming growth factor alpha, tumor necrosis factor receptor superfamily member 9, and macrophage colony-stimulating factor. Rioja I; Hughes FJ; Sharp CH; Warnock LC; Montgomery DS; Akil M; Wilson AG; Binks MH; Dickson MC Arthritis Rheum; 2008 Aug; 58(8):2257-67. PubMed ID: 18668547 [TBL] [Abstract][Full Text] [Related]
10. [Proposal for anti-TNFalpha therapy in adult patients with rheumatoid arthritis]. Curković B; Babić-Naglić D; Morović-Vergles J; Anić B; Grazio S Reumatizam; 2007; 54(1):16-9. PubMed ID: 18450272 [TBL] [Abstract][Full Text] [Related]
11. [Pharmacogenomics of antirheumatic drugs and personalized medicine for rheumatoid arthritis]. Taniguchi A; Urano W; Tanaka E; Kamatani N Nihon Rinsho; 2007 Feb; 65(2):371-9. PubMed ID: 17302286 [TBL] [Abstract][Full Text] [Related]
12. Pharmacogenomics in rheumatoid arthritis. Ranganathan P Methods Mol Biol; 2008; 448():413-35. PubMed ID: 18370240 [TBL] [Abstract][Full Text] [Related]
13. Cardiovascular risk in rheumatoid arthritis: effects of anti-TNF drugs. Avouac J; Allanore Y Expert Opin Pharmacother; 2008 May; 9(7):1121-8. PubMed ID: 18422470 [TBL] [Abstract][Full Text] [Related]
14. Anti-cyclic citrullinated protein antibodies as a predictor of response to anti-tumor necrosis factor-alpha therapy in patients with rheumatoid arthritis. Braun-Moscovici Y; Markovits D; Zinder O; Schapira D; Rozin A; Ehrenburg M; Dain L; Hoffer E; Nahir AM; Balbir-Gurman A J Rheumatol; 2006 Mar; 33(3):497-500. PubMed ID: 16511906 [TBL] [Abstract][Full Text] [Related]
15. Indirect comparisons of the efficacy of biological antirheumatic agents in rheumatoid arthritis in patients with an inadequate response to conventional disease-modifying antirheumatic drugs or to an anti-tumour necrosis factor agent: a meta-analysis. Salliot C; Finckh A; Katchamart W; Lu Y; Sun Y; Bombardier C; Keystone E Ann Rheum Dis; 2011 Feb; 70(2):266-71. PubMed ID: 21097801 [TBL] [Abstract][Full Text] [Related]
16. Predictors of response to TNF inhibitors in rheumatoid arthritis - do we have new tools for personalized medicine? Simsek I Bull NYU Hosp Jt Dis; 2012; 70(3):187-90. PubMed ID: 23259626 [TBL] [Abstract][Full Text] [Related]
17. Personalized medicine in rheumatoid arthritis: hopes and challenges. Bridges SL Bull NYU Hosp Jt Dis; 2007; 65(3):174-7. PubMed ID: 17922665 [TBL] [Abstract][Full Text] [Related]
18. The need for personalised medicine for rheumatoid arthritis. Isaacs JD; Ferraccioli G Ann Rheum Dis; 2011 Jan; 70(1):4-7. PubMed ID: 21068091 [TBL] [Abstract][Full Text] [Related]
19. The relationship between synovial lymphocyte aggregates and the clinical response to infliximab in rheumatoid arthritis: a prospective study. Klaasen R; Thurlings RM; Wijbrandts CA; van Kuijk AW; Baeten D; Gerlag DM; Tak PP Arthritis Rheum; 2009 Nov; 60(11):3217-24. PubMed ID: 19877042 [TBL] [Abstract][Full Text] [Related]
20. Anti-TNFalpha therapy of rheumatoid arthritis: what can we learn about chronic disease? Feldmann M; Brennan FM; Paleolog E; Cope A; Taylor P; Williams R; Woody J; Maini RN Novartis Found Symp; 2004; 256():53-69; discussion 69-73, 106-11, 266-9. PubMed ID: 15027483 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]